Premium
Interferon free therapy with direct acting antivirals for HCV
Author(s) -
Asselah Tarik,
Marcellin Patrick
Publication year - 2013
Publication title -
liver international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.873
H-Index - 110
eISSN - 1478-3231
pISSN - 1478-3223
DOI - 10.1111/liv.12076
Subject(s) - telaprevir , boceprevir , ribavirin , medicine , pegylated interferon , regimen , virology , hepatitis c virus , protease inhibitor (pharmacology) , combination therapy , viral load , immunology , virus , antiretroviral therapy
The current treatment for hepatitis C virus ( HCV ) genotype 1 chronic infection is the addition of direct‐acting antivirals ( DAA ) with a protease inhibitor (telaprevir or boceprevir) to the pegylated interferon ( PEG ‐ IFN ) plus ribavirin ( RBV ) regimen. Major progress has been made in the past few years: numerous ongoing trials with different compounds, increasing sustained virological response ( SVR ) rates with oral regimens and shortened treatment duration. Combinations of antivirals with additive potency that lack cross‐resistance and with a good safety profile may provide new regimens in the future to make HCV the first chronic viral infection to be eradicated worldwide with a finite duration of combination DAA therapy without IFN .